Halozyme Therapeutics, Inc.
HALO
$71.48
$0.751.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 27.06% | -203.34% | 27.89% | 77.12% | 53.72% |
| Total Depreciation and Amortization | 64.96% | 30.69% | 0.29% | 0.84% | 1.20% |
| Total Amortization of Deferred Charges | 21.61% | 5.75% | 0.92% | 0.93% | 0.87% |
| Total Other Non-Cash Items | 218.43% | 5,630.84% | 289.73% | -81.38% | -29.45% |
| Change in Net Operating Assets | -450.62% | -137.17% | -8.05% | -11.86% | -65.34% |
| Cash from Operations | 16.77% | 22.73% | 54.80% | 78.71% | 19.16% |
| Capital Expenditure | -293.79% | 53.24% | -99.74% | 39.47% | 73.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.17% | -144.25% | 223.30% | 318.85% | -13.06% |
| Cash from Investing | 96.82% | -2,616.24% | 220.38% | 301.69% | -9.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 15.65% | -11.21% | -87.32% | -- |
| Repurchase of Common Stock | 51.43% | 100.00% | -- | -- | -579.14% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 51.43% | 197.20% | -220.69% | -3,252.98% | -579.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 190.33% | -636.31% | 1,166.61% | -592.61% | 30.74% |